Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

(2018) Adrian F Hernandez et al.   LANCET

Discovery, characterization, and clinical development of the glucagon-like peptides

(2017) Daniel J. Drucker et al.   JOURNAL OF CLINICAL INVESTIGATION

Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

(2017) Weihao Wang et al.   Diabetes Therapy

Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

(2017) Weihao Wang et al.   Diabetes Therapy

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial

(2016) Bo Ahrén et al.   DIABETES CARE

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial

(2016) Chantal Mathieu et al.   DIABETES CARE

Prevention and Reversal of Type 1 Diabetes—Past Challenges and Future Opportunities

(2015) Jay S. Skyler   DIABETES CARE

Robust meta-analytic-predictive priors in clinical trials with historical control information

(2014) Heinz Schmidli et al.   BIOMETRICS

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes

(2014) Ronnie Aronson et al.   DIABETES CARE

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

(2014) Bo Ahrén et al.   DIABETES CARE

Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action

(2013) Jonathan E. Campbell et al.   Cell Metabolism

Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial

(2013) J. M. Lachin et al.   DIABETES

Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society

(2013) E. R. Seaquist et al.   DIABETES CARE

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: A randomized, open label study

(2013) K.V.S. Hari Kumar et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data

(2012) C. J. Greenbaum et al.   DIABETES

Stopping Type 1 Diabetes: Attempts to Prevent or Cure Type 1 Diabetes in Man

(2010) J. S. Skyler et al.   DIABETES

Time for Testing Incretin Therapies in Early Type 1 Diabetes?

(2010) Emanuele Bosi   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

New Definition for the Partial Remission Period in Children and Adolescents With Type 1 Diabetes

(2009) H. B. Mortensen et al.   DIABETES CARE

Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of  -Cell Function in Therapeutic Trials in Type 1 Diabetes

(2008) C. J. Greenbaum et al.   DIABETES CARE

Exendin-4 Modulates Diabetes Onset in Nonobese Diabetic Mice

(2007) Irene Hadjiyanni et al.   ENDOCRINOLOGY